Скачать или смотреть Professor Ami Klin, Director, Marcus Autism Center, Children’s Healthcare of Atlanta, Georgia

The ARC was pleased to welcome Professor Ami Klin, who gave a presentation entitled: Increasing access to early diagnosis and assessment of autism via objective and cost-effective eye-tracking-based tools

Abstract:
This presentation focuses on studies validating social visual engagement, the moment-by-moment way children look at and learn about their social surroundings, as a quantitative biomarker for autism. Leveraging this science, we have now developed and validated an eye-tracking-based tool for the diagnosis and assessment of autism in 16-30-month toddlers. Following 2 multi-site, prospective, double-blind clinical trials involving more than 1,600 toddlers, including 3 independent cohorts and 3 replications, this tool showed accuracy of a quantitative diagnostic classifier, and of 3 quantitative indices of severity: social disability proxying the total score of the ADOS-2, and verbal and non-verbal age equivalents proxying the verbal and non-verbal scales of the Mullen. This tool was cleared by the US FDA in July of 2023, and it has been in clinical use in the US since August of 2023. Results of the trials appeared in simultaneous publications in JAMA and JAMA Network Open in September of 2023.